Eagle Ridge Investment Management’s Anika Therapeutics ANIK Stock Holding History

Eagle Ridge Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,740	Closed	-$200K	–	153
2018 Q3	$200K	Buy	+4,740	New	+$187K	0.03%	169
2018 Q2	–	Sell	-4,988	Closed	-$248K	–	171
2018 Q1	$248K	Buy	4,988 +248	+5%	+$14K	0.04%	152
2017 Q4	$256K	Buy	4,740 +400	+9%	+$22.1K	0.04%	155
2017 Q3	$252K	Hold	4,340	–	–	0.04%	147
2017 Q2	$214K	Buy	+4,340	New	+$200K	0.04%	127
2017 Q1	–	Sell	-4,610	Closed	-$226K	–	137
2016 Q4	$226K	Hold	4,610	–	–	0.05%	133
2016 Q3	$221K	Hold	4,610	–	–	0.05%	126
2016 Q2	$247K	Sell	4,610 -240	-5%	-$11.3K	0.06%	120
2016 Q1	$217K	Buy	+4,850	New	+$197K	0.05%	118

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Eagle Ridge Investment Management's ANIK Position: Q4 2018 in Review

Eagle Ridge Investment Management sold out of Anika Therapeutics (ANIK) in Q4 2018, closing a stake of 4,740 shares — an estimated $200K sold.

Eagle Ridge Investment Management first reported a position in ANIK in Q1 2016 and held it in 9 quarters. The position peaked at $256K in Q4 2017. 162 funds tracked by Wall St. Rank hold ANIK as of Q4 2018.

Eagle Ridge Investment Management reported no remaining Anika Therapeutics position as of Q4 2018 after selling out during the quarter.
Eagle Ridge Investment Management sold 4,740 Anika Therapeutics shares in Q4 2018, an estimated $200K.
Eagle Ridge Investment Management first reported a position in Anika Therapeutics in Q1 2016 and held it in 9 quarters.
Eagle Ridge Investment Management's Anika Therapeutics position peaked at $256K in Q4 2017.
162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2018.

Based on Eagle Ridge Investment Management's 13F filing for Q4 2018, filed 7 Feb 2019.